Cancer Research · 2016 · 93 citations · 36 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTranscriptional RegulationCancer Cell SignalingEpigenetic Regulation In CancerMyc Family OncogenesOncogene ActivationOncogenic Signaling PathwaysTumor Suppressor GenesHistone AcetylationHistone-lysine AcetylationMyc ActivationMyc In Lung CancerMyc InhibitorsMyc OverexpressionOncogenic Myc SignalingTherapeutic Targeting Of Myc
Dysregulation of MYC expression is a hallmark of cancer, but the development of agents that target MYC has remained challenging. The oncogenic MUC1-C transmembrane protein is, like MYC, aberrantly expressed in diverse human cancers. The present studies demonstrate that MUC1-C induces MYC expression in KRAS mutant non-small cell lung cancer (NSCLC) cells, an effect that can be suppressed by targeting MUC1-C via shRNA silencing, CRISPR editing, or pharmacologic inhibition with GO-203. MUC1-C activated the WNT/β-catenin (CTNNB1) pathway and promoted occupancy of MUC1-C/β-catenin/TCF4 complexes on the MYC promoter. MUC1-C also promoted the recruitment of the p300 histone acetylase (EP300) and, in turn, induced histone H3 acetylation and activation of MYC gene transcription. We also show that targeting MUC1-C decreased the expression of key MYC target genes essential for the growth and survival of NSCLC cells, such as TERT and CDK4. Based on these results, we found that the combination of GO-203 and the BET bromodomain inhibitor JQ1, which targets MYC transcription, synergistically suppressed MYC expression and cell survival in vitro as well as tumor xenograft growth. Furthermore, MUC1 expression significantly correlated with that of MYC and its target genes in human KRAS mutant NSCLC tumors. Taken together, these findings suggest a therapeutic approach for targeting MYC-dependent cancers and provide the framework for the ongoing clinical studies addressing the efficacy of MUC1-C inhibition in solid tumors.
36
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong, F. Ann Ran, David Cox et al. · Science · 2013 · 15.7K citations
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim, Craig H. Mermel, Dale Porter et al. · Nature · 2010 · 4.1K citations · Full text
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text